Utility of EBUS-TBNA in PET-positive mediastinal lymph nodes in subjects with extra-thoracic malignancy.
Bronchoscopy
Endoscopic Ultrasound-Guided Fine Needle Aspiration
/ methods
Female
Humans
Lymph Nodes
/ diagnostic imaging
Lymphatic Metastasis
/ diagnostic imaging
Male
Mediastinal Neoplasms
/ diagnostic imaging
Mediastinum
/ diagnostic imaging
Middle Aged
Neoplasm Staging
Neoplasms
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
Retrospective Studies
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
08
2018
accepted:
21
02
2019
entrez:
12
3
2019
pubmed:
12
3
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Patients with primary extra-thoracic malignancy (ETM) often have hyper-metabolic mediastinal lymph nodes (HM-MLN) in the PET-scan done for initial staging or post treatment follow-up. There is scant data on the etiology of HM-MLN in such patients, which can also be due to non-malignant causes. We used endobronchial ultrasound (EBUS) guided sampling to determine the etiology of HM-MLN in patients with ETM and study the relationship between PET-SUV values and a diagnosis of malignancy in this population. 65 consecutive patients, from March 2013 to March 2017 with either known ETM for primary staging or post-treatment follow-up, with PET CT showing HM-MLN (SUV > 2.5) were included in the study. 65 patients with ETM had EBUS-TBNA for HM-MLN. 20/65 (30.7%) were malignant, 45/65 (69.23%) were benign MLN. In patients with benign etiology of HM-MLN, 6/45 (13.3%) had necrotising granulomatous, 24/45 (53.3%) had non- necrotising granulomatous MLN and 15/45 (33.3%) had reactive MLN. We found discordance (i.e. primary ETM responded to treatment and a new HM-MLN was detected) in 21/65 (32.3%) patients with PET-CT done for initial ETM staging, and 44/65 (67.7%) with a post-treatment PET-CT. showed. Correlating SUV with diagnoses, the SUV values in EBUS-proven malignant MLN were 8.9 ± 4.1, while they were 10.2 ± 5.57 in benign MLN. There was no statistically significant difference between the SUV of benign and malignant MLNs. This study shows a significant incidence of EBUS-TBNA proven benign diagnoses 45/65 (69.2%) in 'SUV-deemed-malignant MLN' and a poor relationship between high SUV and malignant MLN, in patients with known ETM. The ETM related HM-MLN have a significant chance of being benign, and a tissue diagnosis is imperative as it impacts on the treatment plan and prognosis.
Sections du résumé
BACKGROUND/AIM
Patients with primary extra-thoracic malignancy (ETM) often have hyper-metabolic mediastinal lymph nodes (HM-MLN) in the PET-scan done for initial staging or post treatment follow-up. There is scant data on the etiology of HM-MLN in such patients, which can also be due to non-malignant causes. We used endobronchial ultrasound (EBUS) guided sampling to determine the etiology of HM-MLN in patients with ETM and study the relationship between PET-SUV values and a diagnosis of malignancy in this population.
MATERIALS AND METHODS
65 consecutive patients, from March 2013 to March 2017 with either known ETM for primary staging or post-treatment follow-up, with PET CT showing HM-MLN (SUV > 2.5) were included in the study.
RESULTS
65 patients with ETM had EBUS-TBNA for HM-MLN. 20/65 (30.7%) were malignant, 45/65 (69.23%) were benign MLN. In patients with benign etiology of HM-MLN, 6/45 (13.3%) had necrotising granulomatous, 24/45 (53.3%) had non- necrotising granulomatous MLN and 15/45 (33.3%) had reactive MLN. We found discordance (i.e. primary ETM responded to treatment and a new HM-MLN was detected) in 21/65 (32.3%) patients with PET-CT done for initial ETM staging, and 44/65 (67.7%) with a post-treatment PET-CT. showed. Correlating SUV with diagnoses, the SUV values in EBUS-proven malignant MLN were 8.9 ± 4.1, while they were 10.2 ± 5.57 in benign MLN. There was no statistically significant difference between the SUV of benign and malignant MLNs.
CONCLUSION
This study shows a significant incidence of EBUS-TBNA proven benign diagnoses 45/65 (69.2%) in 'SUV-deemed-malignant MLN' and a poor relationship between high SUV and malignant MLN, in patients with known ETM. The ETM related HM-MLN have a significant chance of being benign, and a tissue diagnosis is imperative as it impacts on the treatment plan and prognosis.
Identifiants
pubmed: 30856231
doi: 10.1371/journal.pone.0213437
pii: PONE-D-18-24227
pmc: PMC6411147
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0213437Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Nucl Med. 1994 Nov;35(11):1771-6
pubmed: 7965154
Br J Cancer. 1986 Sep;54(3):467-73
pubmed: 3756082
J Clin Oncol. 2005 Nov 20;23(33):8348-56
pubmed: 16219937
Pathol Res Pract. 2004;200(10):701-5
pubmed: 15648607
J Thorac Cardiovasc Surg. 2008 Mar;135(3):615-9
pubmed: 18329480
Dermatology. 2009;219(1):25-31
pubmed: 19365109
Acta Oncol. 1991;30(3):301-8
pubmed: 2036238
Eur Respir J. 2010 Nov;36(5):1207-9
pubmed: 21037370
Sarcoidosis Vasc Diffuse Lung Dis. 2007 Sep;24(2):95-101
pubmed: 18496978
Turk J Med Sci. 2015;45(6):1234-42
pubmed: 26775376
CMAJ. 1987 Sep 1;137(5):416-7
pubmed: 3040206
Cancer Treat Rev. 1986 Sep;13(3):147-56
pubmed: 3536088
J Dermatol. 1998 Sep;25(9):601-5
pubmed: 9798347
Ann Thorac Med. 2012 Oct;7(4):210-4
pubmed: 23189097
Ear Nose Throat J. 2006 Jun;85(6):397-9
pubmed: 16866119
J Assoc Physicians India. 2014 Jul;62(7):630-2
pubmed: 25672043
Gan. 1982 Jun;73(3):420-8
pubmed: 7129008
Lung Cancer. 2005 Dec;50(3):347-54
pubmed: 16171897
Pathol Oncol Res. 2004;10(3):169-71
pubmed: 15448754
Eur J Gastroenterol Hepatol. 1999 Mar;11(3):353-5
pubmed: 10333212
Korean J Radiol. 2006 Jan-Mar;7(1):57-69
pubmed: 16549957
Urol Oncol. 2010 Jul-Aug;28(4):350-4
pubmed: 19070517
Indian J Tuberc. 2010 Apr;57(2):104-7
pubmed: 21114180
Intern Med. 2011;50(21):2525-32
pubmed: 22041352
Respiration. 2000;67(1):90-3
pubmed: 10705270
Eur Urol. 1997;31 Suppl 1:47-55
pubmed: 9076486
Gen Diagn Pathol. 1997 Jun;142(5-6):347-52
pubmed: 9228259
Ann Oncol. 2005 Oct;16(10):1714-5
pubmed: 15972280
Acta Med Okayama. 2010 Dec;64(6):407-10
pubmed: 21173811
Cancer. 1998 Jul 15;83(2):337-43
pubmed: 9669817
Ann Am Thorac Soc. 2014 Mar;11(3):392-6
pubmed: 24592937
J Thorac Oncol. 2009 Jan;4(1):44-8
pubmed: 19096305
World J Surg Oncol. 2003 Apr 7;1(1):3
pubmed: 12773222
Clin Exp Dermatol. 2005 Sep;30(5):580-2
pubmed: 16045699
Sarcoidosis. 1991 Mar;8(1):51-5
pubmed: 1669941
Acta radiol. 1957 May;47(5):381-92
pubmed: 13434994
Urology. 1993 Feb;41(2):157-9
pubmed: 8497990
Ann Thorac Med. 2011 Jan;6(1):11-6
pubmed: 21264165
Radiographics. 2014 Oct;34(6):1680-91
pubmed: 25310423
Southeast Asian J Trop Med Public Health. 2010 May;41(3):608-13
pubmed: 20578549
Ann Oncol. 2011 Jan;22(1):127-31
pubmed: 20603434